Technology Profile
| Title: | Biomarker for Rheumatic Heart Disease (RHD)- Prototype is Ready for Commercialization |
| Value Proposition: | RHD is diagnosed by ECG. No biochemical marker is avialble for management of RHD. It has found that PICP is robustly increased IN RHD patients. Based on this prototype of the lateral Flow is developed. The test kit would help measurement of clinical activity in quiescent rheumatis heart disease , post penicillin treatment and overall management of the disease. |
| Summary Application: | It is a protein based biomarker, it is detected in serum and urine, This test kit would help measurement of clinical activity in quiescent rheumatic heart disease, post penicillin treatment and overall management of the disease. |
| Advantages: | Measrement of clinical activityin RHD, prognosis and overall management of rhheumatic heart disease. |
| Commercialization Status: | Licensed awaiting commercialisation |
| Tech. Readiness Level: |
: director[at]iicb[dot]res[dot]in
:91-33-24730492
:https://iicb.res.in/
